{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T08:11:49Z","timestamp":1762762309510,"version":"3.41.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,19]]},"DOI":"10.7759\/cureus.86350","type":"journal-article","created":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T13:18:43Z","timestamp":1750339123000},"source":"Crossref","is-referenced-by-count":1,"title":["Radiotherapy for Orbital Myeloid Sarcoma as Extramedullary Relapse in a Pediatric Acute Myeloid Leukemia Patient Post-haploidentical Bone Marrow Transplantation"],"prefix":"10.7759","author":[{"given":"Mohammadhossein","family":"Ghafouri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramesh","family":"Boggula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Nagle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael C","family":"Joiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven R","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2019.04.005","article-title":"Epidemiology of acute myeloid leukemia: recent progress and enduring challenges","volume":"36","author":"Shallis RM","year":"2019","unstructured":"Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev. 2019, 36:70-87. 10.1016\/j.blre.2019.04.005","journal-title":"Blood Rev"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/70.1.49","article-title":"Incidence of childhood cancer: experience of a decade in a population-based registry","volume":"70","author":"Kramer S","year":"1983","unstructured":"Kramer S, Meadows AT, Jarrett P, Evans AE. Incidence of childhood cancer: experience of a decade in a population-based registry. J Natl Cancer Inst. 1983, 70:49-55. 10.1093\/jnci\/70.1.49","journal-title":"J Natl Cancer Inst"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23169","article-title":"Trends in childhood cancer incidence in the U.S. (1992-2004)","volume":"112","author":"Linabery AM","year":"2008","unstructured":"Linabery AM, Ross JA. Trends in childhood cancer incidence in the U.S. (1992-2004). Cancer. 2008, 112:416-32. 10.1002\/cncr.23169","journal-title":"Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber DA","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, et al.. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016, 127:2391-405. 10.1182\/blood-2016-03-643544","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000727","article-title":"Clinicopathological, cytogenetic, and prognostic analysis of 131 myeloid sarcoma patients","volume":"40","author":"Kawamoto K","year":"2016","unstructured":"Kawamoto K, Miyoshi H, Yoshida N, Takizawa J, Sone H, Ohshima K. Clinicopathological, cytogenetic, and prognostic analysis of 131 myeloid sarcoma patients. Am J Surg Pathol. 2016, 40:1473-83. 10.1097\/PAS.0000000000000727","journal-title":"Am J Surg Pathol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-347229","article-title":"How I treat extramedullary acute myeloid leukemia","volume":"118","author":"Bakst RL","year":"2011","unstructured":"Bakst RL, Tallman MS, Douer D, Yahalom J. How I treat extramedullary acute myeloid leukemia. Blood. 2011, 118:3785-93. 10.1182\/blood-2011-04-347229","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13206154","article-title":"Myeloid sarcoma: novel advances regarding molecular pathogenesis, presentation and therapeutic options","volume":"13","author":"Diamantidis MD","year":"2024","unstructured":"Diamantidis MD. Myeloid sarcoma: novel advances regarding molecular pathogenesis, presentation and therapeutic options. J Clin Med. 2024, 13:6154. 10.3390\/jcm13206154","journal-title":"J Clin Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05288-1","article-title":"Myeloid sarcoma: more and less than a distinct entity","volume":"102","author":"Loscocco GG","year":"2023","unstructured":"Loscocco GG, Vannucchi AM. Myeloid sarcoma: more and less than a distinct entity. Ann Hematol. 2023, 102:1973-84. 10.1007\/s00277-023-05288-1","journal-title":"Ann Hematol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s12905-021-01328-y","article-title":"The myeloid sarcoma treated by venetoclax with hypomethylating agent followed by stem cell transplantation: rare case report","volume":"21","author":"Shatilova A","year":"2021","unstructured":"Shatilova A, Girshova L, Zaytsev D, et al.. The myeloid sarcoma treated by venetoclax with hypomethylating agent followed by stem cell transplantation: rare case report. BMC Womens Health. 2021, 21:184. 10.1186\/s12905-021-01328-y","journal-title":"BMC Womens Health"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.lrr.2021.100286","article-title":"Bladder myeloid sarcoma with TP53 mutated myelodysplastic syndrome\/myeloproliferative neoplasm overlap syndrome: response to decitabine-venetoclax regimen","volume":"17","author":"Mandhan N","year":"2022","unstructured":"Mandhan N, Yassine F, Li K, Badar T. Bladder myeloid sarcoma with TP53 mutated myelodysplastic syndrome\/myeloproliferative neoplasm overlap syndrome: response to decitabine-venetoclax regimen. Leuk Res Rep. 2022, 17:100286. 10.1016\/j.lrr.2021.100286","journal-title":"Leuk Res Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1177\/10781552221110826","article-title":"Orbital myeloid sarcoma treated with low-dose venetoclax and a potent cytochrome P450 inhibitor","volume":"29","author":"De la Garza-Salazar F","year":"2023","unstructured":"De la Garza-Salazar F, Pe\u00f1a-Lozano SP, G\u00f3mez-Almaguer D, Colunga-Pedraza PR. Orbital myeloid sarcoma treated with low-dose venetoclax and a potent cytochrome P450 inhibitor. J Oncol Pharm Pract. 2023, 29:493-7. 10.1177\/10781552221110826","journal-title":"J Oncol Pharm Pract"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2011.02.057","article-title":"Radiation therapy for chloroma (granulocytic sarcoma)","volume":"82","author":"Bakst R","year":"2012","unstructured":"Bakst R, Wolden S, Yahalom J. Radiation therapy for chloroma (granulocytic sarcoma). Int J Radiat Oncol Biol Phys. 2012, 82:1816-22. 10.1016\/j.ijrobp.2011.02.057","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100773","article-title":"Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: a tale of misnomers, controversy and the unresolved","volume":"47","author":"Shallis RM","year":"2021","unstructured":"Shallis RM, Gale RP, Lazarus HM, et al.. Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: a tale of misnomers, controversy and the unresolved. Blood Rev. 2021, 47:100773. 10.1016\/j.blre.2020.100773","journal-title":"Blood Rev"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2018.05.045","article-title":"Use of radiation in extramedullary leukemia\/chloroma: guidelines from the International Lymphoma Radiation Oncology Group","volume":"102","author":"Bakst RL","year":"2018","unstructured":"Bakst RL, Dabaja BS, Specht LK, Yahalom J. Use of radiation in extramedullary leukemia\/chloroma: guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2018, 102:314-9. 10.1016\/j.ijrobp.2018.05.045","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-8-245","article-title":"Clinicopathologic features and responses to radiotherapy of myeloid sarcoma","volume":"8","author":"Chen WY","year":"2013","unstructured":"Chen WY, Wang CW, Chang CH, et al.. Clinicopathologic features and responses to radiotherapy of myeloid sarcoma. Radiat Oncol. 2013, 8:245. 10.1186\/1748-717X-8-245","journal-title":"Radiat Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(83)90176-1","article-title":"Extramedullary lesions in non-lymphocytic leukemia: results of radiation therapy","volume":"9","author":"Chak LY","year":"1983","unstructured":"Chak LY, Sapozink MD, Cox RS. Extramedullary lesions in non-lymphocytic leukemia: results of radiation therapy. Int J Radiat Oncol Biol Phys. 1983, 9:1173-6. 10.1016\/0360-3016(83)90176-1","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200310000-00004","article-title":"Extramedullary leukemia in children with newly diagnosed acute myeloid leukemia: a report from the Children's Cancer Group","volume":"25","author":"Dusenbery KE","year":"2003","unstructured":"Dusenbery KE, Howells WB, Arthur DC, et al.. Extramedullary leukemia in children with newly diagnosed acute myeloid leukemia: a report from the Children's Cancer Group. J Pediatr Hematol Oncol. 2003, 25:760-8. 10.1097\/00043426-200310000-00004","journal-title":"J Pediatr Hematol Oncol"},{"key":"ref18","doi-asserted-by":"crossref","DOI":"10.1097\/00002820-199310000-00006","article-title":"Acute and long-term effects of radiation therapy to the eye in children","volume":"16","author":"Servodidio CA","year":"1993","unstructured":"Servodidio CA, Abramson DH. Acute and long-term effects of radiation therapy to the eye in children. Cancer Nurs. 1993, 16:371-81.","journal-title":"Cancer Nurs"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2023.06.007","article-title":"Retinopathy, optic neuropathy, and cataract in childhood cancer survivors treated with radiation therapy: a PENTEC comprehensive review","volume":"119","author":"Shen CJ","year":"2024","unstructured":"Shen CJ, Kry SF, Buchsbaum JC, et al.. Retinopathy, optic neuropathy, and cataract in childhood cancer survivors treated with radiation therapy: a PENTEC comprehensive review. Int J Radiat Oncol Biol Phys. 2024, 119:431-45. 10.1016\/j.ijrobp.2023.06.007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2011.07.024","article-title":"Dosimetric study of current treatment options for radiotherapy in retinoblastoma","volume":"82","author":"Eldebawy E","year":"2012","unstructured":"Eldebawy E, Parker W, Abdel Rahman W, Freeman CR. Dosimetric study of current treatment options for radiotherapy in retinoblastoma. Int J Radiat Oncol Biol Phys. 2012, 82:e501-5. 10.1016\/j.ijrobp.2011.07.024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-017-0819-7","article-title":"Dosimetric advantage of volumetric modulated arc therapy in the treatment of intraocular cancer","volume":"12","author":"Deng Z","year":"2017","unstructured":"Deng Z, Shen L, Zheng X, et al.. Dosimetric advantage of volumetric modulated arc therapy in the treatment of intraocular cancer. Radiat Oncol. 2017, 12:83. 10.1186\/s13014-017-0819-7","journal-title":"Radiat Oncol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2021.575","article-title":"Radiation-induced ocular surface disorders and retinopathy: ocular structures and radiation dose-volume effect","volume":"54","author":"Akagunduz OO","year":"2022","unstructured":"Akagunduz OO, Yilmaz SG, Tavlayan E, Baris ME, Afrashi F, Esassolak M. Radiation-induced ocular surface disorders and retinopathy: ocular structures and radiation dose-volume effect. Cancer Res Treat. 2022, 54:417-23. 10.4143\/crt.2021.575","journal-title":"Cancer Res Treat"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl AE","year":"2019","unstructured":"Perl AE, Martinelli G, Cortes JE, et al.. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019, 381:1728-40. 10.1056\/NEJMoa1902688","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo CD","year":"2019","unstructured":"DiNardo CD, Pratz K, Pullarkat V, et al.. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019, 133:7-17. 10.1182\/blood-2018-08-868752","journal-title":"Blood"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3390\/ph16111614","article-title":"A review of childhood acute myeloid leukemia: diagnosis and novel treatment","volume":"16","author":"Tseng S","year":"2023","unstructured":"Tseng S, Lee ME, Lin PC. A review of childhood acute myeloid leukemia: diagnosis and novel treatment. Pharmaceuticals (Basel). 2023, 16:1614. 10.3390\/ph16111614","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.31286","article-title":"Venetoclax for pediatric patients with newly diagnosed acute myeloid leukemia","volume":"71","author":"Gibson A","year":"2024","unstructured":"Gibson A, Dickson S, McCall D, et al.. Venetoclax for pediatric patients with newly diagnosed acute myeloid leukemia. Pediatr Blood Cancer. 2024, 71:e31286. 10.1002\/pbc.31286","journal-title":"Pediatr Blood Cancer"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14302","article-title":"Venetoclax combined with FLAG-IDA in refractory or relapsed acute myeloid leukemia","volume":"114","author":"Wille K","year":"2025","unstructured":"Wille K, Dumke M, Wilsdorf N, et al.. Venetoclax combined with FLAG-IDA in refractory or relapsed acute myeloid leukemia. Eur J Haematol. 2025, 114:17-25. 10.1111\/ejh.14302","journal-title":"Eur J Haematol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402958","article-title":"Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy","volume":"17","author":"Tsimberidou AM","year":"2003","unstructured":"Tsimberidou AM, Kantarjian HM, Estey E, et al.. Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy. Leukemia. 2003, 17:1100-3. 10.1038\/sj.leu.2402958","journal-title":"Leukemia"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1159\/000253592","article-title":"Prognostic factors of treatment outcomes in patients with granulocytic sarcoma","volume":"122","author":"Lan TY","year":"2009","unstructured":"Lan TY, Lin DT, Tien HF, Yang RS, Chen CY, Wu K. Prognostic factors of treatment outcomes in patients with granulocytic sarcoma. Acta Haematol. 2009, 122:238-46. 10.1159\/000253592","journal-title":"Acta Haematol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.23201","article-title":"Superior outcome of pediatric acute myeloid leukemia patients with orbital and CNS myeloid sarcoma: a report from the Children's Oncology Group","volume":"58","author":"Johnston DL","year":"2012","unstructured":"Johnston DL, Alonzo TA, Gerbing RB, Lange BJ, Woods WG. Superior outcome of pediatric acute myeloid leukemia patients with orbital and CNS myeloid sarcoma: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2012, 58:519-24. 10.1002\/pbc.23201","journal-title":"Pediatr Blood Cancer"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2020.100806","article-title":"Orbital myeloid sarcoma (chloroma): report of 2 cases and literature review","volume":"19","author":"AlSemari MA","year":"2020","unstructured":"AlSemari MA, Perrotta M, Russo C, et al.. Orbital myeloid sarcoma (chloroma): report of 2 cases and literature review. Am J Ophthalmol Case Rep. 2020, 19:100806. 10.1016\/j.ajoc.2020.100806","journal-title":"Am J Ophthalmol Case Rep"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-10831-7","article-title":"Clinical characteristics, treatment, and prognosis of 118 cases of myeloid sarcoma","volume":"12","author":"Zhao H","year":"2022","unstructured":"Zhao H, Dong Z, Wan D, et al.. Clinical characteristics, treatment, and prognosis of 118 cases of myeloid sarcoma. Sci Rep. 2022, 12:6752. 10.1038\/s41598-022-10831-7","journal-title":"Sci Rep"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-008-9028-x","article-title":"Orbital tumour as initial manifestation of acute myeloid leukemia: granulocytic sarcoma: case report","volume":"14","author":"Maka E","year":"2008","unstructured":"Maka E, Luk\u00e1ts O, T\u00f3th J, Fekete S. Orbital tumour as initial manifestation of acute myeloid leukemia: granulocytic sarcoma: case report. Pathol Oncol Res. 2008, 14:209-11. 10.1007\/s12253-008-9028-x","journal-title":"Pathol Oncol Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/345559-radiotherapy-for-orbital-myeloid-sarcoma-as-extramedullary-relapse-in-a-pediatric-acute-myeloid-leukemia-patient-post-haploidentical-bone-marrow-transplantation","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T13:18:44Z","timestamp":1750339124000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/345559-radiotherapy-for-orbital-myeloid-sarcoma-as-extramedullary-relapse-in-a-pediatric-acute-myeloid-leukemia-patient-post-haploidentical-bone-marrow-transplantation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,19]]},"references-count":33,"URL":"https:\/\/doi.org\/10.7759\/cureus.86350","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,19]]}}}